Dr. Pan was recruited through the ‘Hundred Talents Program’ of Sun Yat-sen University and granted with ‘Shenzhen Peacock Program’ to join the Seventh Affiliated Hospital of Sun Yat-sen University, where he serves as Vice President of the Seventh Affiliated Hospital, Associate Researcher, Master's Supervisor and Director of Precision Medicine Research Center.
Pan achieved his Ph.D. degree in Cell Biology from Louisiana State University Medical Center. He later on was dedicated to postdoctoral research at the pathology department of Cornell University School of Medicine. Meanwhile, he served as a clinical fellow at the American College of Medical Genetics and Genomics (ACMG). Additionally, Dr. Pan is the Secretary-General of CASB and has membership in AACR, ASCB, SAPA and other renowned associations.
Dr. Pan had worked in the Pathology Department of the Affiliated Hospital of Cornell Medical College for six years, in which He had engaged in the clinical work of gene detection and diagnosis and accumulated rich clinical experience in interpreting genetic factors in relation to diseases and health. Dr. Pan has published more than 20 SCI papers and a chapter of a medical book. Furthermore, he served as a peer reviewer for many SCI journals.
Dr. Pan is dedicated to clinical medicine, diagnostic practice and medical research in both China and the United States for more than 20 years. His working commitment is mainly focusing on searching for early diagnostic markers and therapeutic targets of tumours at the level of human genes by using genome sequencing and other techniques. He also researches the development of diagnostic reagents, targeted drugs, and identifying the role of gene diagnosis in disease prevention, intervention, individualised treatment that contribute to further clinical practice and scientific research.
Programs and Subjects:
BIOLOGY OF TAXANE RESPONSE IN THE CONTEXT OF ETS REARRANGED PRO，2010-2011
2. Department of Defense New Investigator Award，PC081337，CHARATERIZATION OF PROSTATE CANCER REARRANGMENTS，2008-2009
3. National Institutes of Health (NIH)/National Cancer Institute，R01 CA125612，TOWARDS UNDERSTANDING PROSTATE CANCER HETEROGENEITY,2007-2011
4. National Institutes of Health grant，NS-35317，GLIAL FILAMENT ASSOCIATED PROTEINS IN HUMAN ASTROCYTOMAS，2003-2006
Publication:
（1）Huang Y#, Xu Z, Xiong S, Sun F, Qin G, Hu G, Wang J, Zhao L, Liang YX, Wu T, Lu Z, Humayun MS, So KF, Pan Y, Li N, Yuan TF, Rao Y, Peng B*.Repopulated microglia have solely derived from the proliferation of residual microglia after acute depletion. Nature Neuroscience, 2018.2.22, 0(0): 1~19.
（2）Pan Y. #, Jing R., Pitre A., Williams J., and Skalli O*. Intermediate filament protein synemin contributes to the migratory properties of astrocytoma cells by influencing the dynamics of the actin cytoskeleton. FASEB J. 2008; 22(9):3196-206.
（3）Liao L. #, Song M., Li X., Tang L., Zhang T., Zhang L., Pan Y., Chouchane L., Ma X*. Novel role of E3 ubiquitin protein ligase UBR5 in tumor growth and metastasis of triple negative breast cancer. Cancer Res, 2017.4.15, 77(8): 2090~2101.
（4）Rickman DS. #, Chen Y., B anerjee S., Pan Y., Yu J, Vuong T, Perner S., Lafargue CJ., Mertz KD., Setlur SR., Sircar K.,Chinnaiyan AM.,Bismar TA., Rubin MA. *, and Demichelis F*. ERG Cooperates with Androgen Receptor in Regulating Trefoil Factor 3 in Prostate Cancer Disease Progression. Neoplasia. 2010; 11(12):1031-40.
（5）Pflueger D. #, Rickman DS., Sboner A., Perner S., LaFargue CJ., Svensson MA., Moss BJ., Kitabayashi N., Pan Y., Taille A., Kuefer R., Tewari AK., Demichelis F., Chee MS., Gerstein MB., and Rubin MA*. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia. 2009; 11(8):804-811.
（6）Jing R. #; Wilhelmsson U.; Goodwill W.; Li L.; Pan Y.; Pekny M.; Skalli O*. Synemin is expressed in reactive astrocytes in neurotrauma and interacts differentially with vimentin and GFAP intermediate filament networks. Journal of Cell Science, 2007.4.1, 120(7): 1267~77.
（7）Sun YL. #, Kumar P., Sodani K., Patel A., Pan Y., Baer MR., Chen ZS., and Jiang WQ*. Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncology Reports. 2014; 31(4): 1605-1612.
（8）Luedtuke D. #, Niu X., Pan Y., Zhao J., Liu S., Edwards H., Wang G., Lin H., Taub JW., and Ge Y*. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor Venetoclax in AML cells. Signal Transduct Target Ther, 2017.4.7, 2: 17012~17020.
（9）Vispute SG. #, Chen JJ., Sun YL., Sodani K., Singh S., Pan Y., Talele TT., Ashby CR., and Chen ZS*. Vemurafenib (PLX4032, Zelboraf®), a BRAF Inhibitor, Modulates ABCB1-, ABCG2-, and ABCC10-Mediated Multidrug Resistance. Journal of Cancer Research Updates. 2013; 2(4):306-317.
（10）Pitre A. #, Pan Y., Pruett S., and Skalli O*. On the use of ratio standard curves to accurately quantitate relative changes in protein levels by Western blot. Anal. Biochem. 2007; 361(2):305-7.
Email Address：panyih@mail.sysu.edu.cn